Physician profile
Erik M Long
NPI 1609834621
$1,933.90
in general payments reported to CMS, 2019-2025
27 companies · $619 in 2025
The $619 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.99 · 2020: $48.86 · 2021: $235 · 2022: $265 · 2023: $140 · 2024: $532 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,291.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $915.94 | 2021-2025 | |
| Pfizer INC. | $85.71 | 2019-2024 | |
| Novo Nordisk INC | $72.55 | 2019-2025 | Rybelsus, Wegovy, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $68.60 | 2022-2024 | |
| Insulet Corporation | $64.62 | 2025 | Omnipod |
| Otsuka America Pharmaceutical, INC. | $60.95 | 2022-2025 | Rexulti |
| Allergan, INC. | $59.68 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.33 | 2021-2022 | |
| Corcept Therapeutics | $51.97 | 2024-2025 | Korlym |
| Biogen, INC. | $46.73 | 2024 | Zurzuvae |
| Astrazeneca Pharmaceuticals LP | $46.50 | 2022-2023 | Farxiga |
| Teva Pharmaceuticals USA, INC. | $42.88 | 2025 | Austedo Xr |
| Boston Scientific Corporation | $42.87 | 2023 | Wavewriter Alpha Prime 16 |
| Lundbeck LLC | $36.56 | 2025 | Rexulti |
| Medtronic, INC. | $34.20 | 2025 | Inceptiv |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $28.57 | 2021 | |
| Lilly USA, LLC | $27.56 | 2022-2025 | Zepbound, Mounjaro |
| Dexcom, INC. | $26.87 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.35 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $23.39 | 2024 | Ingrezza |
| Viatris Specialty LLC | $21.64 | 2025 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $19.99 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.15 | 2024 | Caplyta |
| Glaxosmithkline, LLC. | $15.83 | 2019 | |
| Exact Sciences Corporation | $15.02 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $14.50 | 2019 | |
| Scilex Pharmaceuticals INC. | $13.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.